|
KMID : 0853020100130020116
|
|
Journal of Korean Burn Society
2010 Volume.13 No. 2 p.116 ~ p.120
|
|
|
Effect of Recombinant Basic Fibroblast Growth Factor (Fiblastⓡ) in Treatment with Chronic Soft Tissue Defect
|
|
Lee Min-Jae
Yun In-Sik
Rah Dong-Kyun
Lee Won-Jae
|
|
|
Abstract
|
|
|
Purpose: Chronic soft tissue defects resulting from pressure sore, trauma or comorbid disease such as diabetes, osteomyelitis are difficult to treat. Although many advances have been made, consensus on the best treatment to hasten healing of chronic soft tissue defects has not been reached. Recently, it has been found that the wound healing could be
accelerated by the action of growth factors. Fibroblast growth factor (FGF) stimulate proliferation and differentiation of neuroectodermal and mesodermal tissues (endothelial cells and fibroblasts), playing a key role in regeneration of granulation tissues. We report the effect of recombinant basic fibroblast growth factor, Fiblastⓡ (Kaken Pharmaceutical, Japan) to chronic soft tissue defect.
Methods: From October 2009 to December 2009, 10 patients (7 men and 3 women) with chronic soft tissue defect
were treated using bFGF. Average age, sex, treatment period, cause of soft tissue defect, size (volume, cm3) of wound
during treatment, investigator global assessment were assessed. The bFGF was sprayed then foam dressing was
applied to soft tissue defects.
Results: The average treatment period is 18.6 days (6∼45days) and the average age is 41.5 (4∼73 years old).
Among 10 patients, 7 patients were with pressure sore and other 3 were with trauma, postoperative wound, burn. The
size of wound was measured by volume (cm3), and it was decreased 49.5% (0∼100%) after treatment. The Average investigator global assessment for these subjects was 2.4 on a 0∼3 scale. (3; excellent, 2; good, 1; minimal effective, 0; no effective). No complication was seen locally or systemically with bFGF.
Conclusion: Using of bFGF for chronic soft tissue defect decreased the size of wound while short period. Clinically, wound treatment with bFGF lead to reduction of the surgery area and healing of wound. Additional researches on investigating the different type of wounds, biological effects and underlying mechanisms are needed.
|
|
|
KEYWORD
|
|
|
Fibroblast growth factor, Fibroblast growth factor 2, Wounds and injuries
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|